• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

肝脏移植: 中山医科大学器官移植中心的经验

Liver transplantation at the Sun Yat-Sen University of Medical Sciences in China

摘要:

目的总结70例肝脏移植治疗不同终末期肝病的经验,探讨肝移植在治疗肝细胞癌(HCC)和重症乙型肝炎的疗效,以及评价拉米夫定对预防乙肝复发的应用价值.方法回顾性分析了自1993年4月至2000年12月本中心实施的70例肝移植临床资料.肝移植的主要指征是原发性肝癌(26例)、肝硬化(21例)、重症乙型肝炎(12例)、硬化性胆管炎(4 例)以及其它终末期肝病(7例).对12例重症性乙型肝炎患者应用拉米夫定治疗.采用多元回归分析确定影响肝移植预后的危险因素.结果 54例患者存活1个月以上,16例患者在移植术后30天内死亡,院内存活率为77.1%,肝功能属Child A级和B级的患者院内存活率明显高于Child C级患者(P<0 .05),小肝癌患者的疗效优于大肝癌患者.移植前APACEⅢ评分,腹水量以及血肌酐水平与肝移植预后有密切关系.在重症乙肝患者中,9例仍存活,存活时间为2-24个月,拉米夫定可有效抑制肝移植术后乙肝复发,且无明显的副作用. 结论本研究结果显示原位肝移植可使部分HCC病人获得治愈,部分病例可获得良好的姑息疗效. 病例选择对肝癌肝移植的预后极其重要;结果还提示肝移植作为一种治疗各种终末期肝病的手段是可行的.同时认为拉米夫定是一种疗效肯定,副作用小的预防肝移植术后乙肝病毒复发的药物.

更多
abstracts:

Objectives To summarize the results of liver transplantation for various end-stage liver diseases at the Sun Yat-Sen University of Medical Sciences (SUMS), define the role of liver transplantation in the treatment of hepatocellular carcinoma and fulminant hepatitis B, and assess the efficiency of lamivudine on preventing HBV recurrence.Methods Seventy liver transplants performed at the SUMS between April 1993 and December 2000 were retrospectively analyzed. The main indications for liver transplant were hepatocellular carcinoma (26 cases), liver cirrhosis (21 cases), fulminant hepatitis B (12 cases), sclerosing cholangitis (4 cases) and other terminal liver diseases (7 cases). Lamivudine was used in twelve patients suffering from fulminant hepatitis B. Logistic multivariate regression analysis was applied to determine the risk factors predicting liver transplantation outcomes.Results Fifty-four patients survived for more than one month, and 16 patients died within 30 days after orthotopic liver transplantation (OLT). The overall hospital survival rate was 77.1%. The hospital survival rates in the Child's A and B patients were 87.5% and 83.3%, respectively. Those rates were superior to those of the Child's C patients (P<0.05). The outcome of patients with small hepatocellular carcinoma (HCC) was superior to that of patients with large HCC. Preoperative APACE Ⅲ scores, the severity of ascites and serum creatine level had independent influence on outcome. Of the patients with fulminant HBV infection, 9 recipients survived for a follow-up period of 2-24 months. Treatment with lamivudine monotherapy was both well tolerated and efficacious in patients with fulminant hepatitis B.Conclusions The results indicate that orthotopic liver transplantation could provide long-term cure and palliation for patients with HCC, and that patient selection is extremely important in predicting outcome. The results support the continued application of liver transplantation as a therapeutic modality for various end-stage liver diseases and that lamivudine is an effective and safe monotherapy in OLT for patients with HBV infection.

More
作者: 黄洁夫 [1] 何晓顺 [1] 陈规划 [1] 朱晓峰 [1] 陆敏强 [1] 王国栋 [1] 傅宇阳 [1] 杨扬 [1] 管向东 [1]
期刊: 《中华医学杂志(英文版)》2002年115卷4期 543-548页 SCIMEDLINEISTICCSCDBP
分类号: R65
栏目名称: 论著
DOI: 10.3760/cma.j.issn.0366-6999.2002.04.115
发布时间: 2004-01-08
基金项目:
key clinical project grant of the Ministry of Health key project grant of the Scientific and Technological Committee of Guangdong Province
翻译满意度评价:
提交
  • 浏览:514
  • 下载:20

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷